{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073401","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.992147+00:00","generated_at":"2026-05-15T23:59:26.464401+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1","bullets":["Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.","FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.","Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.","FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.","EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073401","json":"https://secwatch.observer/filing/0001193125-26-073401.json","markdown":"https://secwatch.observer/filing/0001193125-26-073401.md","text":"https://secwatch.observer/filing/0001193125-26-073401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/0001193125-26-073401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/d106406d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:59:26.464401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}